ecancer

ecancer presents a free live interactive webinar on the latest in #bladdercancer on 29th July 17:00 BST/18:00 CEST. Register here for expert analysis 📷ecancer.org/bladder #ASCOGU26 #AUA26 #ASCO26 @AlisonBirtle @nachoduranm @LAUrology_NL @MRoupret @giannatempopatr

🌍 The WHO Global Status Report on Cancer 2026 calls for people-centred, equitable cancer care. Better access, stronger health systems, and patient-centred innovation are key to improving outcomes. 📖 shorturl.at/nl6gW #CancerControl #GlobalHealth #WHO

📖 LECTURA RECOMENDADA ¿Cuál es el futuro del tratamiento del carcinoma renal metastásico? En #ASCO2026 se han revisado las últimas evidencias en inmunoterapia y terapias combinadas. Un panel de expertos internacionales — entre ellos el Dr. Guillermo de Velasco @g_develasco— ha debatido los datos más relevantes en mRCC presentados esta semana en Chicago. 👇 Os dejamos el resumen completo vía @ecancer ecancer.org/en/video/12804… #CancerRenal #GUOncology #GUARDConsortium #ASCO2026 #Inmunoterapia @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🚨 Proud to share our new ARON-3 study, now in European Urology Oncology. @OncoAlert @aron_project @APCCC_Lugano Doublet vs triplet therapy in high-volume mHSPC with bone metastases: real-world outcomes from an international collaboration. Honored to be part of this work with dear colleagues across the ARON network. 📊 Key findings: 🔵 841 pts with CHAARTED-defined high-volume mHSPC 🔵 75% received doublet therapy; 25% received triplet therapy 🔵 Triplet therapy was associated with improved ECOG-PS dynamics and reduced opioid use at 12 weeks 🔵 In pts with >10 bone metastases, triplet therapy showed better TTF vs doublet therapy 🔵 OS was numerically favorable but not statistically significant 💡 Clinical message: Not every high-volume mHSPC patient may need the same level of intensification. Bone metastatic burden may help refine patient selection for triplet therapy — but prospective validation is essential. sciencedirect.com/science/articl… @EUplatinum @Uroweb @LauBernalOnc @raymanneh @SoaresAndrey @fsabino_onco @fmassari79 @BourlonMaite @Uromigos @Silke_Gillessen @AOmlin #ProstateCancer #mHSPC #GUOncology #ARON3 #RealWorldEvidence #OncoTwitter

📚 Leer los datos es importante. 👏 @BrianRiniMD @tompowles1 🎙️ Escuchar cómo expertos los interpretan, los cuestionan y los traducen a la práctica clínica puede ser aún más valioso. Qué bueno ver que @LosUromigos sigue expandiendo contenido en español para la comunidad oncológica hispanohablante. Más acceso. Más educación. Más conversación científica. 🌎 @ecancer @OncoAlert @LacortMedical @SolcaGuayaquil @spuurologia @smumexico @LalcecArgentina @UBAMedicina @UBAonline @SauUrologia @SolcaGuayaquil @BrasilOncologia #GUOnc #ASCO26 #Oncologia #MedEd

Broadcasting live in 1 hour, tune in to our free webinar.....ecancer.org/bcqualitycare #breastcancer #surgery #healthpolicy

Happy to see more than 1000 views on this @ecancer video of #ASCO26 highlights from @oncology_bg within one week of the ASCO meeting being over. This is truly your Best of ASCO in 40 mins. ecancer.org/en/video/12984…

Last week, we had 4 videos come out. 1. Highlights from #ASCO26 @ecancer: ecancer.org/en/video/12984… 2. On draxonrasib, the new pancreatic cancer drug trial, for @CBCTheNational : cbc.ca/news/health/ex… youtu.be/D0s3SU_S6Gk?si… 3. On interpreting clinical trials @MedscapeOnc medscape.com/viewarticle/to… 4. On 5 fallacies in Medicine @Medscape medscape.com/viewarticle/fa…

Last week, we had 4 videos come out. 1. Highlights from #ASCO26 @ecancer: ecancer.org/en/video/12984… 2. On draxonrasib, the new pancreatic cancer drug trial, for @CBCTheNational : cbc.ca/news/health/ex… youtu.be/D0s3SU_S6Gk?si… 3. On interpreting clinical trials @MedscapeOnc medscape.com/viewarticle/to… 4. On 5 fallacies in Medicine @Medscape medscape.com/viewarticle/fa…

New paper published in @ecancer on travel burden for patients with colorectal cancer in Kashmir, India. ecancer.org/en/journal/art… The first author of this paper is Dr. Saquib Banday who was paired with @oncology_bg for 2022 @myESMO virtual mentorship program.

New #openaccess paper published in @ecancer ! ecancer.org/en/journal/art… Led by Dr. Saquib Banday, my mentee from the @myESMO 2022 Virtual Mentorship Program, we look at travel burden among patients with colorectal cancer in the resource limited settings of Kashmir, India. We find that - in very simplified terms- living farther away from cancer center is associated with worse outcomes unless you’re rich enough to rent an apartment nearby.

Honored to discuss key messages perioperative #PROTEUS data and the precision-medicine signal from #TALAPRO-3 in HRR-altered mHSPC @ecancer @OncoAlert @EfstathiouEleni @ProfHadaschik @urotoday ecancer.org/en/video/12975…

Hey everyone, want to catchup on the latest highlights from #ASCO26 ? I cover all plenary trials and other important studies. My @ecancer highlights video is now up! Check it out. ecancer.org/en/video/12984…

Hey it’s out! The thing that you’ve been waiting for is out! BG’s @ecancer #ASCO26 highlights video is now live. Watch for a bias-free commentary on the most important takeaways from this year’s @ASCO meeting. ecancer.org/en/video/12984…

At #ASCO26, Dr Marchetti @clamarchetti81 presented findings showing that short-term fasting improved chemotherapy response and prolonged progression-free survival in advanced #ovariancancer. Watch the interview now ▶️ecancer.org/en/video/12978…

Can radiotherapy be safely reduced for selected patients with HPV-associated #oropharyngealcancer? At #ASCO26, Dr @imrtlee indicates that FMISO PET-guided radiation de-escalation maintained excellent outcomes while reducing treatment intensity for most. ecancer.org/en/video/12977…

Could tarlatamab improve outcomes for patients with #smallcelllungcancer and #brainmetastases? At #ASCO26, Dr Mountzios reviews data showing improved intracranial PFS, OS, and brain response rates with tarlatamab compared with chemotherapy. @g_mountzios ecancer.org/en/video/12959…

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26

New data presented at #ASCO26 by Dr McDonald suggests that GLP-1 therapies may be linked to a lower incidence of #BreastCancer in women. Watch the interview now 👇ecancer.org/en/video/12973…

Why are younger adults with #GastrointestinalCancers experiencing worse outcomes? At #ASCO26, Dr Paulus from @OntadaOncology highlights higher rates of advanced-stage disease and significant racial disparities among patients diagnosed before age 50. ecancer.org/en/video/12961…